Caspase-1 inhibitor Ac-YVAD-cmk prohibits humoral immunity response in EAMG (experimental autoimmune myasthenia gravis) rats via suppressing IL-6/STAT3/Bcl-6 pathways, providing insights for the development of APS therapy methods (105). This evidence concerns the gene IL6 and autoimmune polyendocrinopathy.